Moody’s downgrades Senegal to Caa1 amid rising debt concerns
Investing.com -- Bluejay Diagnostics Inc (NASDAQ:BJDX) stock soared 110% in premarket trading Thursday after the company announced an expanded manufacturing partnership with Japan’s SanyoSeiko Co., Ltd.
The medical diagnostics company, which focuses on developing rapid near-patient testing solutions, has amended its Master Service and Master Supply Agreements with SanyoSeiko to broaden the Japanese firm’s role in commercializing Bluejay’s Symphony platform.
Under the expanded agreement, SanyoSeiko will provide comprehensive support for the Symphony platform, including manufacturing redevelopment for analyzers and cartridges, raw material sourcing, and serving as Bluejay’s contract manufacturing organization. The Japanese partner will also handle fulfillment, kit assembly, labeling, packaging, shipping, and quality control.
The Symphony platform is designed to deliver rapid and reliable results for key biomarkers such as IL-6 in sepsis management.
"This expanded partnership marks a key milestone in Bluejay’s commercialization strategy for the Symphony platform," said Neil Dey, CEO of Bluejay. "By formalizing SanyoSeiko’s role as manufacturing partner, we strengthen our supply chain resilience, secures high-quality production capacity, and advances readiness for broader clinical validation and market introduction."
Futoshi Shirakawa, CEO of SanyoSeiko, added that the company’s "technical capabilities and manufacturing experience will support the successful commercialization of Symphony, a platform with the potential to make a meaningful impact in critical care diagnostics worldwide."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.